AnGesAMGXF 53 Days Payable is 252.28 as of Dec. 2025, which is 61% below its 10-year median of 642.08. GuruFocus rates AMGXF with a GF Score™ of 53/100 and a GF Value™ of $0.74. The stock has 5 warning signs investors should review. Among 699 Biotechnology companies, AnGes ranks better than 65.81% on this metric.
AnGes's average Accounts Payable for the
three
months ended in Dec. 2025 was $2.95 Mil. AnGes's Cost of Goods Sold for the
three
months ended in Dec. 2025 was $1.07 Mil.
Hence, AnGes's Days Payable for the
three
months ended in Dec. 2025 was 252.28.
The historical rank and industry rank for AnGes's Days Payable or its related term are showing as below:
AMGXF'
s Days Payable Range Over the Past 10 Years
Min: 221.16 Med: 642.08 Max: 5526.9
Current: 221.16
During the past 13 years, AnGes's highest Days Payable was 5526.90. The lowest was 221.16. And the median was 642.08.
AMGXF's Days Payable is ranked better than 65.81% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs AMGXF: 221.16
AnGes's Days Payable
increased
from Dec. 2024 (193.03) to Dec. 2025 (252.28).
It may suggest that AnGesdelayed paying its suppliers.
AnGes Days Payable Related Terms
AnGes Days Payable Historical Data
* Premium members only.
The historical data trend for AnGes's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMGXF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, AnGes's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnGes Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnGes's Days Payable distribution charts can be found below:
* The bar in red indicates where AnGes's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AnGes's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnGes (AMGXF) has a Days Payable of 252.28 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AnGes and its competitors. This is 61% below median its historical median of 642.08. Over the past decade, AnGes' Days Payable has ranged from 221.16 to 5,526.90. According to the industry distribution chart, AnGes ranks #239 out of 699 companies in the Biotechnology industry, placing it in the top 34.2%.
Is AnGes' Days Payable too high?
AnGes' current Days Payable of 252.28 is 61% below median its 10-year median of 642.08. Over the past 10 years, this metric has ranged from a low of 221.16 to a high of 5,526.90. The Biotechnology industry median Days Payable is 112.84. AnGes' value of 252.28 is 123.6% above this industry median. Based on the distribution chart, AnGes ranks #239 out of 699 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AnGes has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does AnGes' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AnGes ranks #239 out of 699 companies for Days Payable. This puts AnGes in the upper half of its industry. The industry median Days Payable is 112.84. AnGes' value of 252.28 is 123.6% above this benchmark. Historically, AnGes' own Days Payable has ranged from 221.16 to 5,526.90 over the past decade. While the company's 10-year median is 642.08 vs. the industry median of 112.84, AnGes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AnGes's current Days Payable of 252.28 is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AnGes and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnGes's current Days Payable is 252.28, which is 61% below median its own 10-year median of 642.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnGes stock overvalued right now?
AnGes (AMGXF) has a current Days Payable of 252.28. The stock's GF Value™ is $0.74, compared to a current price of $0.36 — trading 51.3% below its estimated fair value. The current Days Payable is 252.28, which is 61% below median its 10-year median of 642.08 and 123.6% above the Biotechnology industry median of 112.84. AnGes' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AnGes (AMGXF), the current Days Payable is 252.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnGes (AMGXF) Overvalued in 2026?
Based on GuruFocus' analysis, AnGes stock appears to be undervalued.
The current stock price of $0.36 is trading 51.3% below its estimated GF Value™ of $0.74.
Key valuation signals for AMGXF:
Days Payable: 252.28 (61% below median its 10-year median of 642.08)
GF Value™: $0.74 vs. price of $0.36 (51.3% below fair value)
Industry Position: 123.6% above the Biotechnology median (#239 of 699)
No single metric tells the full story. See the AMGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnGes Inc is a biopharmaceutical company. The company is involved in research and development and sales of pharmaceuticals such as gene-based drugs (gene therapy products, nucleic acid drugs); contract testing for rare genetic diseases, etc.
53GF Score
Get the complete analysis for AMGXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMGXF has been successfully added to your 
